公表論文
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects
Fouqueray P — 2020
Deuterium-enabled chiral switching (DECS) yields chirally pure drugs from chemically interconverting racemates
Dewitt S — 2020
Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents
Perry RJ — 2016
Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration
Detaille D — 2016
Imeglimin: a potential new multi-target drug for Type 2 diabetes
Vulsteke — 2015
Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes
Pacini G — 2015
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy
Fouqueray P — 2014
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy
Fouqueray P — 2013